PALISADE BIO, INC. PALI
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 ("PDE4") inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease ("IBD"), including ulcerative colitis ("UC") and Crohn's disease ("CD").
We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.
•advancing our lead clinical product candidate, PALI-2108, towards a Phase 2 clinical study in UC designed to evaluate clinical remission response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission;
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250.0K | $0 | — | $13.5K | $15.4K | $260.0K | $260.0K | $16.2K |
| R&D | — | $16.0M | — | — | — | $2.0M | $4.1M | $4.0M | $8.1M | $13.2M |
| SG&A | $7.9M | $5.8M | $6.2M | $8.8M | $9.3M | $6.2M | $4.6M | $4.6M | $5.5M | $7.5M |
| Total operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M | $9.3M | $8.6M | $8.5M | $13.6M | $20.7M |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M | -$9.3M | -$8.6M | -$8.3M | -$13.3M | -$20.6M |
| Interest expense | $10.0K | $12.0K | $15.0K | $13.0K | $2.4M | $235.0K | $8.9K | $7.7K | $159.1K | $1.1M |
| Pre-tax income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | -$26.6M | -$10.3M | — | — | — | -$21.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $1.0K | — | — | — | $0 |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | -$26.6M | -$10.3M | -$8.4M | -$4.9M | -$15.7M | -$21.1M |
| EPS, basic | -0.30 | -10.19 | -27.01 | -16.53 | -142.95 | -3.72 | — | — | — | — |
| EPS, diluted | -0.30 | -10.19 | -27.01 | -16.53 | -169.74 | -3.72 | -3.80 | -7.54 | -1.20 | -2.53 |
| Shares, diluted (wtd. avg.) | 55.7M | 1.4M | 456,014 | 880,311 | 186,958 | 2.8M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M | $713.0K | $5.1M | $5.8M | $6.7M | $15.2M |
| Short-term investments | — | — | — | — | — | — | — | — | $5.0M | $5.0M |
| Receivables | — | — | — | — | $0 | $59.0K | $21.1K | $294.1K | $312.8K | $10.5K |
| Total current assets | $134.2M | $10.5M | $13.3M | $14.7M | $11.5M | $896.0K | $5.6M | $6.5M | $12.4M | $20.9M |
| Property, plant and equipment | $0 | $3.0K | $10.0K | $10.0K | $3.0K | $5.0K | $41.0K | $90.3K | $172.9K | $269.6K |
| Other intangibles | — | — | — | — | — | $147.1K | $668.9K | $763.5K | $883.5K | $990.2K |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M | $3.0M | $6.6M | $7.7M | $13.9M | $22.6M |
| Accounts payable | $767.0K | $1.1M | $698.0K | $1.8M | $1.3M | $2.5M | — | — | — | — |
| Short-term debt | — | — | — | — | $87.0K | $1.0M | — | — | — | $3.7M |
| Total current liabilities | $4.6M | $3.2M | $2.6M | $3.0M | $2.5M | $8.1M | $1.2M | $1.1M | $1.5M | $7.3M |
| Long-term debt | — | — | — | — | $0 | $94.0K | — | — | — | — |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M | $10.1M | $1.5M | $1.6M | $5.4M | $11.3M |
| Retained earnings | — | $135.9M | $121.5M | $109.2M | $94.6M | -$238.2M | -$222.0M | -$213.6M | -$208.7M | -$193.0M |
| Total equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M | -$16.6M | -$8.3M | $6.0M | $8.5M | $11.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M | -$4.8M | -$7.3M | -$7.7M | -$13.4M | -$15.6M |
| Depreciation and amortisation | $3.0K | $3.0K | $4.0K | $3.0K | — | $29.0K | $49.0K | $84.0K | $100.0K | $161.0K |
| Stock-based compensation | $4.0M | $652.0K | $624.0K | $1.0M | $1.9M | $2.0M | $880.8K | $634.1K | $1.8M | $3.4M |
| Capital expenditure | — | $0 | $4.0K | $10.0K | $0 | $6.0K | — | $1.7K | $11.4K | $98.1K |
| Investing cash flow | — | $0 | -$4.0K | -$10.0K | -$54.0K | -$6.0K | — | $5.0M | -$94.0K | $2.4M |
| Financing cash flow | $134.4M | $9.6M | $11.2M | $15.3M | $24.6M | $1.9M | $6.6M | $1.8M | $5.0M | $23.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-019629.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.2K | $260.0K | $260.0K | $15.4K | $13.5K | — | $0 | $250.0K | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$21.1M | -$15.7M | -$4.9M | -$8.4M | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Charter or fiscal year changed Item 5.03
- Shareholder vote Item 5.07
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |